Literature DB >> 26987905

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin.

T Balligand1,2, Y Achouri3, C Pecquet1,2, I Chachoua1,2, H Nivarthi4, C Marty5,6,7, W Vainchenker5,6,7, I Plo5,6,7, R Kralovics4, S N Constantinescu1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26987905     DOI： 10.1038/leu.2016.47

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  JAK inhibitor in CALR-mutant myelofibrosis.

Authors:  Francesco Passamonti; Domenica Caramazza; Margherita Maffioli
Journal:  N Engl J Med       Date:  2014-03-20       Impact factor: 91.245

Review 2.  Calreticulin: one protein, one gene, many functions.

Authors:  M Michalak; E F Corbett; N Mesaeli; K Nakamura; M Opas
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

3.  A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses.

Authors:  F Kohlhuber; N C Rogers; D Watling; J Feng; D Guschin; J Briscoe; B A Witthuhn; S V Kotenko; S Pestka; G R Stark; J N Ihle; I M Kerr
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

4.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

5.  Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.

Authors:  Ilyas Chachoua; Christian Pecquet; Mira El-Khoury; Harini Nivarthi; Roxana-Irina Albu; Caroline Marty; Vitalina Gryshkova; Jean-Philippe Defour; Gaëlle Vertenoeil; Anna Ngo; Ann Koay; Hana Raslova; Pierre J Courtoy; Meng Ling Choong; Isabelle Plo; William Vainchenker; Robert Kralovics; Stefan N Constantinescu
Journal:  Blood       Date:  2015-12-14       Impact factor: 22.113

6.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

7.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113

8.  Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA.

Authors:  Daisuke Mashiko; Yoshitaka Fujihara; Yuhkoh Satouh; Haruhiko Miyata; Ayako Isotani; Masahito Ikawa
Journal:  Sci Rep       Date:  2013-11-27       Impact factor: 4.379

9.  Thrombopoietin receptor is required for the oncogenic function of CALR mutants.

Authors:  H Nivarthi; D Chen; C Cleary; B Kubesova; R Jäger; E Bogner; C Marty; C Pecquet; W Vainchenker; S N Constantinescu; R Kralovics
Journal:  Leukemia       Date:  2016-02-17       Impact factor: 11.528

10.  MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling.

Authors:  K Kollmann; J Nangalia; W Warsch; H Quentmeier; A Bench; E Boyd; M Scott; H G Drexler; A R Green
Journal:  Leukemia       Date:  2014-09-24       Impact factor: 11.528
View more
  21 in total

1.  Absence of CALR mutations in JAK2-negative polycythemia.

Authors:  Aurélie Chauveau; Olivier Nibourel; Sylvie Tondeur; Damien Luque Paz; Olivier Mansier; Franciane Paul; Mathieu Wemeau; Claude Preudhomme; Eric Lippert; Valérie Ugo
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

2.  Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.

Authors:  Katte Rao Toppaldoddi; Maira da Costa Cacemiro; Olivier Bluteau; Barbara Panneau-Schmaltz; Amélie Pioch; Delphine Muller; Jean-Luc Villeval; Hana Raslova; Stefan N Constantinescu; Isabelle Plo; William Vainchenker; Caroline Marty
Journal:  Oncogene       Date:  2018-10-19       Impact factor: 9.867

Review 3.  Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.

Authors:  Ruochen Jia; Robert Kralovics
Journal:  Int J Hematol       Date:  2019-11-18       Impact factor: 2.490

Review 4.  Myeloproliferative neoplasms: from origins to outcomes.

Authors:  Jyoti Nangalia; Anthony R Green
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Authors:  L Falchi; H M Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

6.  Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.

Authors:  Manjola Balliu; Laura Calabresi; Niccolò Bartalucci; Simone Romagnoli; Laura Maggi; Rossella Manfredini; Matteo Lulli; Paola Guglielmelli; Alessandro Maria Vannucchi
Journal:  Blood Adv       Date:  2021-04-27

7.  Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms.

Authors:  Jessica Petiti; Marco Lo Iacono; Valentina Rosso; Giacomo Andreani; Aleksandar Jovanovski; Marina Podestà; Dorela Lame; Marco De Gobbi; Carmen Fava; Giuseppe Saglio; Francesco Frassoni; Daniela Cilloni
Journal:  J Cell Mol Med       Date:  2020-08-13       Impact factor: 5.310

8.  Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation.

Authors:  Stefan A Brooks; Daniel M Kim; Sarah J Morse; Quy H Nguyen; Brianna M Craver; Hew Yeng Lai; Angela G Fleischman
Journal:  Leuk Res       Date:  2019-05-09       Impact factor: 3.156

9.  Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.

Authors:  Thomas Balligand; Younes Achouri; Christian Pecquet; Gilles Gaudray; Didier Colau; Eva Hug; Yacine Rahmani; Vincent Stroobant; Isabelle Plo; William Vainchenker; Robert Kralovics; Benoît J Van den Eynde; Jean-Philippe Defour; Stefan N Constantinescu
Journal:  Leukemia       Date:  2019-08-30       Impact factor: 11.528

Review 10.  The Role of Megakaryocytes in Myelofibrosis.

Authors:  Johanna Melo-Cardenas; Anna Rita Migliaccio; John D Crispino
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-11       Impact factor: 3.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.